Knights of Columbus Asset Advisors LLC Acquires New Stake in Oruka Therapeutics, Inc. $ORKA

Knights of Columbus Asset Advisors LLC bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,996 shares of the company’s stock, valued at approximately $1,166,000.

Several other institutional investors have also recently made changes to their positions in the company. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $29,000. GAMMA Investing LLC boosted its position in shares of Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares in the last quarter. Orion Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $91,000. Sterling Capital Management LLC grew its stake in Oruka Therapeutics by 839.0% in the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares during the period. Finally, Royal Bank of Canada grew its stake in Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after purchasing an additional 2,033 shares during the period. Institutional investors own 56.44% of the company’s stock.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the completion of the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at approximately $1,146,051.40. This trade represents a 41.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This represents a 7.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 169,950 shares of company stock valued at $15,426,080. 23.49% of the stock is owned by corporate insiders.

Key Headlines Impacting Oruka Therapeutics

Investors following ORKA have been watching these headlines:

• Positive Sentiment: BTIG Research and UBS each initiated or reiterated a “Buy” view on Oruka Therapeutics, signaling analyst confidence. BTIG Research Buy-rating article UBS Buy-rating article
• Negative Sentiment: HC Wainwright lowered its quarterly and full-year EPS estimates through 2027, including its FY2027 forecast from a loss of $2.82 to a loss of $3.22 per share. The analyst maintained a Buy rating, but the deeper projected losses may weigh on sentiment.
• Negative Sentiment: A newly disclosed patent-expiry risk could expose Oruka to earlier generic competition and pressure future revenue. Patent-expiry risk article

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Wedbush restated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. Finally, Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $141.80.

Oruka Therapeutics Trading Down 2.0%

Shares of NASDAQ ORKA opened at $104.99 on Friday. The firm’s 50 day moving average price is $89.39 and its 200-day moving average price is $72.01. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). As a group, research analysts expect that Oruka Therapeutics, Inc. will post -2.50 earnings per share for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.